Physician profile
Thomas Fowler
NPI 1861948176
$6,719.80
in general payments reported to CMS, 2019-2025
36 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $482 · 2021: $884 · 2022: $647 · 2023: $1,128 · 2024: $1,124 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,571 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.25 |
| Education | $122.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $886.39 | 2020-2025 | Dupixent |
| Genzyme Corporation | $769.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $730.15 | 2020-2025 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $696.08 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $588.20 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Biocryst US Sales Co., LLC | $506.96 | 2021-2025 | Orladeyo |
| Csl Behring | $286.74 | 2019-2025 | Hizentra, Privigen, Andembry |
| Grifols USA, LLC | $266.34 | 2021-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Octapharma USA, INC. | $262.30 | 2021-2025 | Cutaquig |
| Pfizer INC. | $256.40 | 2021-2024 | |
| Genentech USA, INC. | $174.79 | 2019-2024 | Xolair |
| Amgen INC. | $145.05 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $135.95 | 2019-2025 | Ruconest |
| Kaleo, INC. | $120.28 | 2023-2024 | Auvi-Q |
| Horizon Therapeutics Plc | $102.93 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $92.85 | 2021-2025 | Odactra, Ragwitek, Grastek |
| Jubilant Hollisterstier LLC | $86.68 | 2025 | |
| Novartis Pharmaceuticals Corporation | $73.86 | 2021-2025 | |
| Biocryst Pharmaceuticals, INC. | $68.04 | 2020 | |
| Henry Schein, INC. | $67.22 | 2023 | |
| Qol Medical, LLC | $49.24 | 2021-2022 | |
| Galderma Laboratories, L.P. | $37.70 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $34.49 | 2024-2025 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $29.33 | 2025 | Dawnzera |
| Sanofi-Aventis U.S. LLC | $27.91 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $27.39 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $25.62 | 2022 | |
| Covis Pharma Gmbh | $25.47 | 2023 | |
| Abbvie INC. | $21.98 | 2024 | |
| Merck Sharp & Dohme LLC | $21.23 | 2021 | |
| Lilly USA, LLC | $19.79 | 2025 | |
| Leo Pharma INC. | $18.39 | 2024 | Adbry |
| Greer Laboratories, INC. | $18.27 | 2024 | Palforzia |
| Insmed, INC. | $17.38 | 2025 | |
| Blueprint Medicines Corporation | $15.57 | 2024 | Ayvakit |
| Optinose US, INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.